跳转至内容
Merck
CN

主要文件

查看所有文档

SML3647

Ulifloxacin

≥98% (HPLC)

别名:

6-Fluoro-1-methyl-4-oxo-7-(1-piperazinyl)-1H,4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid, AF 3013, NAD 394, NM 394

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:
C16H16FN3O3S
化学文摘社编号:
112984-60-8
分子量:
349.38
UNSPSC Code:
51111800
NACRES:
NA.77
MDL number:
MFCD00882994
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

Fc1cc2c(cc1N4CCNCC4)N3C(SC3=C(C2=O)C(=O)O)C

InChI

1S/C16H16FN3O3S/c1-8-20-11-7-12(19-4-2-18-3-5-19)10(17)6-9(11)14(21)13(16(22)23)15(20)24-8/h6-8,18H,2-5H2,1H3,(H,22,23)

InChI key

SUXQDLLXIBLQHW-UHFFFAOYSA-N

Biochem/physiol Actions

Orally available, broad-spectrum fluoroquinolone antibacterial agent that potently inhibits bacterial DNA gyrase and topoisomerase IV
Ulifloxacin is an orally available, broad-spectrum fluoroquinolone antibacterial agent. Ulifloxacin is an active metabolite of Prulifloxacin. It potently inhibits bacterial DNA gyrase and topoisomerase IV.

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Warning

Hazard Classifications

Lact. - Skin Irrit. 2 - STOT RE 2

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000244476
0000244475
0000238751
0000244476
0000244475

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Susan J Keam et al.
Drugs, 64(19), 2221-2234 (2004-10-01)
Prulifloxacin, the prodrug of ulifloxacin, is a broad-spectrum oral fluoroquinolone antibacterial agent. After absorption, prulifloxacin is metabolised by esterases to ulifloxacin. The drug has a long elimination half-life, allowing once-daily administration. Ulifloxacin is generally more active in vitro than other
Valeria Tellone et al.
Drugs in R&D, 18(3), 237-245 (2018-08-29)
The antibacterial agent prulifloxacin, a prodrug of ulifloxacin, is indicated in the treatment of acute lower urinary tract infections, acute exacerbation of chronic bronchitis and acute bacterial rhinosinusitis. We aimed to provide new insights on the pharmacokinetics (PK) of ulifloxacin
Marcello Locatelli et al.
Journal of enzyme inhibition and medicinal chemistry, 31(1), 106-111 (2015-02-17)
A new and specific HPLC-DAD method for the direct determination of Prulifloxacin and its active metabolite, Ulifloxacin, in human plasma has been developed. Plasma samples were analysed after a simple solid phase extraction (SPE) clean-up using a new HILIC stationary

全球贸易项目编号

货号GTIN
SML3647-10MG04065269791799
SML3647-50MG04065269791805